https://www.fiercepharma.com/pharma/m-a-large-biotech-pharma-companies-will-have-1-7t-firepower-for-dealmaking-2022
Based on the companies’ cash positions and potential room to take on new debt, Porges said the 18 biopharma majors will have $1.72 trillion in M&A capacity. J&J topped the list with more than $200 billion in M&A firepower. Pfizer and Novartis followed with $175 billion and $154 billion, respectively. AbbVie, GSK, Bristol Myers Squibb and Merck will each boast more than $100 billion in firepower, the team figures.
J&J Partnership, page-357
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
-0.010(1.61%) |
Mkt cap ! $145.8M | |||
| Open | High | Low | Value | Volume |
| 62.5¢ | 63.0¢ | 61.0¢ | $1.181M | 1.913M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5445 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |